RNA療法臨床試験市場- 世界の産業規模、シェア、動向、機会、予測、2018～2028年、モダリティ別、フェーズ別、治療領域別、地域別、競合、予測、機会、2028年

世界のRNA療法臨床試験市場は、2022年に26億2,000万米ドルの評価を記録し、予測期間中に大幅な成長が見込まれ、予想年間平均成長率（CAGR）は5.06％で、2028年には34億9,000万米ドルに達すると予測されています。

医学研究の最先端分野であるRNA療法は、さまざまな疾患に対する革新的な治療法を開発するための有望な手段として浮上してきました。この新しいアプローチは、リボ核酸（RNA）の力を利用して遺伝子発現を調節し、治療効果をもたらします。

市場概要：

世界のRNA療法臨床試験市場は近年大きな牽引力を得ており、医療の展望に革命をもたらし、これまで治療不可能だった疾患に対する潜在的な解決策を提供しています。RNA療法は、メッセンジャーRNA（mRNA）、低分子干渉RNA（siRNA）、アンチセンスオリゴヌクレオチド（ASO）などのRNA分子を利用して特定の遺伝子を標的とし、その活性を制御するという原理に基づいています。この精密ベースのアプローチは、遺伝性疾患、感染症、がん、さらには有効な治療法のない希少疾患への対応に計り知れない可能性を秘めています。従来の医薬品とは異なり、RNA療法は遺伝子レベルでの介入を目的としており、より的を絞った個別化治療を提供できる可能性があります。

主な市場促進要因

1.RNA技術の急速な進歩：

RNA技術の急速な進歩は、世界のRNA療法臨床試験市場を大きく押し上げ、医学研究と医療の展望に革命をもたらしています。こうしたブレークスルーは、広範な疾患や病態に対応できる可能性を秘めた革新的なRNAベースの治療法の開発を後押ししています。

2.mRNAワクチンの成功：

mRNAワクチンの大成功は、世界のRNA治療臨床試験市場全体に波及し、医学研究と治療開発のパラダイムシフトを促しています。mRNAワクチンの前例のない成果は、RNAベースの治療法の計り知れない可能性を明らかにし、この分野の加速的な進歩に拍車をかけました。

3.技術革新：

技術革新は世界のRNA療法臨床試験市場の原動力となっており、医学研究と治療開発の展望を変える変革的進歩をもたらしています。これらの技術革新は、RNAベースの治療の成功に不可欠なさまざまな分野にまたがり、課題を克服し、有効性を高め、最先端科学の具体的な臨床応用への転換を加速する可能性を秘めています。

主な市場課題

1.デリバリーの課題：

送達の課題は、世界のRNA治療臨床試験市場にとって重要な側面であり、RNAベースの治療を安全かつ効果的に投与するために研究開発者が克服しなければならない複雑なハードルです。これらの課題の中心は、RNA分子を体内の特定の細胞や組織にうまく送達することであり、これは望ましい治療効果を得るための基本的な条件です。

2.安定性と半減期：

安定性と半減期は、世界のRNA治療臨床試験市場において極めて重要な考慮事項であり、RNAベースの治療法の有効性、安全性、実用性を決定する上で極めて重要な役割を果たしています。これらの要素は、RNA分子の治療可能性と、持続的かつ望ましい結果をもたらす能力に直接影響を与えます。

主な市場動向：

1.個別化医療と精密医療：

個別化医療と精密医療は、世界のRNA治療臨床試験市場における変革的なアプローチであり、個人の遺伝情報を活用して治療効果を高め、副作用を最小限に抑えるオーダーメイド治療の新時代を告げるものです。

2.遺伝子編集の統合：

遺伝子編集の統合は、世界のRNA治療臨床試験市場において画期的なフロンティアであり、RNAに基づく治療と高度な遺伝子編集技術の融合により、遺伝子レベルでの標的を絞った正確な介入のための新たな道が開かれつつあります。

セグメント別洞察：

モダリティ別洞察：

2022年、RNA治療臨床試験市場は、主にmRNAベースの予防接種の使用と様々な疾患状態におけるその可能性により、メッセンジャーRNAセグメントによって支配されました。

フェーズ別洞察：

2022年、RNA療法の臨床試験市場は、RNA療法の理想的な投与量と投与レジメンを決定する上で重要な役割を果たす第II相臨床試験が支配的でした。

地域別洞察：

2022年、北米は早期導入、強固な研究インフラ、良好な規制環境、強力なバイオテクノロジーおよび製薬産業により、RNA療法臨床試験市場をリードしました。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のRNA療法臨床試験市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • モダリティ別（RNA干渉、アンチセンス療法、メッセンジャーRNA、オリゴヌクレオチド、非アンチセンス、非RNAi）
  • フェーズ別（フェーズi、フェーズII、フェーズIII、フェーズIV）
  • 治療領域別（希少疾患、抗感染症、抗がん、神経、消化器/代謝、筋骨格系、心血管系呼吸器、感覚器、その他）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2022年）
• 製品市場マップ
  • モダリティ別
  • フェーズ別
  • 治療領域別
  • 地域別

第6章 北米のRNA療法臨床試験市場展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • モダリティ別
  • フェーズ別
  • 治療領域別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のRNA療法臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • モダリティ別
  • フェーズ別
  • 治療領域別
  • 国別
• 欧州：国別分析
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋のRNA治療臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • モダリティ別
  • フェーズ別
  • 治療領域別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア

第9章 南米のRNA療法臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • モダリティ別
  • フェーズ別
  • 治療領域別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのRNA療法臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • モダリティ別
  • フェーズ別
  • 治療領域別
  • 国別
• 中東・アフリカ：国別分析
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品開発

第13章 臨床試験分析

第14章 競合情勢

• IQVIA
• ICON Plc
• Laboratory Corporation of America Holdings
• Charles River Laboratories International, Inc.
• PAREXEL International Corp.
• Syneos Health
• Medpace Holdings, Inc.
• Novotech
• Veristat, LLC.

第15章 戦略的提言

The Global RNA Therapy Clinical Trials Market recorded a valuation of USD 2.62 Billion in 2022 and is expected to experience substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 5.06% and expected to reach USD 3.49 Billion through 2028. RNA therapy, a cutting-edge field of medical research, has emerged as a promising avenue for developing innovative treatments for a wide range of diseases. This novel approach harnesses the power of ribonucleic acid (RNA) to modulate gene expression and provide therapeutic benefits.

Market Overview:

The global RNA therapy clinical trials market has gained significant traction in recent years, revolutionizing the healthcare landscape and offering potential solutions for previously untreatable conditions. RNA therapy operates on the principle of utilizing RNA molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), to target specific genes and regulate their activity. This precision-based approach holds immense potential for addressing genetic disorders, infectious diseases, cancer, and even rare conditions that lack effective treatment options. Unlike traditional pharmaceuticals, RNA therapies aim to intervene at the genetic level, potentially providing more targeted and personalized treatments.

Key Market Drivers:

1. Rapid Advancement in RNA Technology:

Rapid advances in RNA technology have significantly propelled the Global RNA Therapy Clinical Trials Market, revolutionizing the landscape of medical research and healthcare. These breakthroughs are driving the development of innovative RNA-based therapies with the potential to address a wide spectrum of diseases and conditions.

2. Success of mRNA Vaccines:

The resounding success of mRNA vaccines has reverberated across the Global RNA Therapy Clinical Trials Market, catalyzing a paradigm shift in medical research and therapeutic development. The unprecedented achievements of mRNA vaccines have illuminated the immense potential of RNA-based therapies and spurred accelerated advancements in the field.

3. Technological Innovation:

Technological innovation stands as a driving force within the Global RNA Therapy Clinical Trials Market, ushering in transformative advancements that are reshaping the landscape of medical research and therapeutic development. These innovations span a range of areas critical to the success of RNA-based therapies and hold the potential to overcome challenges, enhance efficacy, and accelerate the translation of cutting-edge science into tangible clinical applications.

Key Market Challenges:

1. Delivery Challenges:

Delivery challenges are a critical aspect of the Global RNA Therapy Clinical Trials Market, representing a complex hurdle that researchers and developers must overcome to ensure the safe and effective administration of RNA-based therapies. These challenges center around the successful and targeted delivery of RNA molecules to specific cells or tissues within the body, a fundamental requirement for achieving the desired therapeutic outcomes.

2. Stability and Half-Life:

Stability and half-life are crucial considerations in the Global RNA Therapy Clinical Trials Market, playing a pivotal role in determining the effectiveness, safety, and practicality of RNA-based therapies. These factors directly impact the therapeutic potential of RNA molecules and their ability to deliver sustained and desired outcomes.

Key Market Trends:

1. Personalized and Precision Medicine:

Personalized and precision medicine represents a transformative approach within the Global RNA Therapy Clinical Trials Market, heralding a new era of tailored treatments that leverage individual genetic information to enhance therapeutic efficacy and minimize adverse effects.

2. Gene Editing Integration:

Gene editing integration represents a groundbreaking frontier within the Global RNA Therapy Clinical Trials Market, where the convergence of RNA-based therapies and advanced gene editing technologies is unlocking new avenues for targeted and precise interventions at the genetic level.

Segmental Insights:

Modality Insights:

In 2022, the RNA Therapy Clinical Trials Market was dominated by the messenger RNA segment, primarily due to the use of mRNA-based vaccinations and their potential in various disease states.

Phase Insights:

In 2022, the RNA Therapy Clinical Trials Market was dominated by phase II clinical trials, as they play a crucial role in determining the ideal dose and dosing regimen for RNA therapies.

Regional Insights:

In 2022, North America led the RNA Therapy Clinical Trials Market due to early adoption, robust research infrastructure, a favorable regulatory environment, and a strong biotechnology and pharmaceutical industry.

In conclusion, the Global RNA Therapy Clinical Trials Market is poised for significant growth, driven by rapid advancements in RNA technology, the success of mRNA vaccines, and ongoing technological innovations. While challenges such as delivery and stability must be addressed, the integration of personalized medicine and gene editing holds promise for reshaping the landscape of medical care and treatment.

Key Market Players

• IQVIA
• ICON Plc
• Laboratory Corporation of America Holdings
• Charles River Laboratories International, Inc.
• PAREXEL International Corp.
• Syneos Health
• Medpace Holdings, Inc.
• Novotech
• Veristat, LLC.
• Veristat, LLC.

Report Scope:

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

2. Global RNA Therapy Clinical Trials Market, By Modality:

• RNA interference
• Antisense therapy Messenger RNA
• Oligonucleotide
• Non-antisense
• Non-RNAi

3. Global RNA Therapy Clinical Trials Market, By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

4. Global RNA Therapy Clinical Trials Market, By Therapeutic Area:

• Rare Diseases
• Anti-infective
• Anticancer
• Neurological
• Alimentary/Metabolic
• Musculoskeletal
• Cardiovascular Respiratory
• Sensory
• Others

5. Global RNA Therapy Clinical Trials Market, By Region:

• North America
  • 1. United States
  • 2. Canada
  • 3. Mexico

• Europe
  • 1. Germany
  • 2. France
  • 3. United Kingdom
  • 4. Italy
  • 5. Spain

• Asia-Pacific
  • 1. China
  • 2. Japan
  • 3. India
  • 4. South Korea
  • 5. Australia
  • 6. Singapore

• South America
  • 1. Brazil
  • 2. Argentina
  • 3. Colombia

• Middle East & Africa
  • 1. UAE
  • 2. Saudi Arabia
  • 3. South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

6. Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Types
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global RNA Therapy Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
  • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Modality
  • 5.3.2. By Phase
  • 5.3.3. By Therapeutic Areas
  • 5.3.4. By Region

6. North America RNA Therapy Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Modality
  • 6.2.2. By Phase
  • 6.2.3. By Therapeutic Areas
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Therapy Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Modality
      • 6.3.1.2.2. By Phase
      • 6.3.1.2.3. By Therapeutic Areas
  • 6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Modality
      • 6.3.2.2.2. By Phase
      • 6.3.2.2.3. By Therapeutic Areas
  • 6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Modality
      • 6.3.3.2.2. By Phase
      • 6.3.3.2.3. By Therapeutic Area

7. Europe RNA Therapy Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Modality
  • 7.2.2. By Phase
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Modality
      • 7.3.1.2.2. By Phase
      • 7.3.1.2.3. By Therapeutic Area
  • 7.3.2. France RNA Therapy Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Modality
      • 7.3.2.2.2. By Phase
      • 7.3.2.2.3. By Therapeutic Area
  • 7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Modality
      • 7.3.3.2.2. By Phase
      • 7.3.3.2.3. By Therapeutic Area
  • 7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Modality
      • 7.3.4.2.2. By Phase
      • 7.3.4.2.3. By Therapeutic Area
  • 7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Modality
      • 7.3.5.2.2. By Phase
      • 7.3.5.2.3. By Therapeutic Area

8. Asia-Pacific RNA Therapy Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Modality
  • 8.2.2. By Phase
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNA Therapy Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Modality
      • 8.3.1.2.2. By Phase
      • 8.3.1.2.3. By Therapeutic Area
  • 8.3.2. Japan RNA Therapy Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Modality
      • 8.3.2.2.2. By Phase
      • 8.3.2.2.3. By Therapeutic Area
  • 8.3.3. India RNA Therapy Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Modality
      • 8.3.3.2.2. By Phase
      • 8.3.3.2.3. By Therapeutic Area
  • 8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Modality
      • 8.3.4.2.2. By Phase
      • 8.3.4.2.3. By Therapeutic Area
  • 8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Modality
      • 8.3.5.2.2. By Phase
      • 8.3.5.2.3. By Therapeutic Area

9. South America RNA Therapy Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Modality
  • 9.2.2. By Phase
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Modality
      • 9.3.1.2.2. By Phase
      • 9.3.1.2.3. By Therapeutic Area
  • 9.3.2. Argentina RNA Therapy Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Modality
      • 9.3.2.2.2. By Phase
      • 9.3.2.2.3. By Therapeutic Area
  • 9.3.3. Colombia RNA Therapy Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Modality
      • 9.3.3.2.2. By Phase
      • 9.3.3.2.3. By Therapeutic Area

10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Modality
  • 10.2.2. By Phase
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE RNA Therapy Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Modality
      • 10.3.1.2.2. By Phase
      • 10.3.1.2.3. By Therapeutic Area
  • 10.3.2. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Modality
      • 10.3.2.2.2. By Phase
      • 10.3.2.2.3. By Therapeutic Area
  • 10.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Modality
      • 10.3.3.2.2. By Phase
      • 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Type
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Company Snapshot
• 14.3. Products & Services
• 14.4. Financials (As Reported)
• 14.5. Recent Developments
  • 14.5.1. IQVIA
  • 14.5.2. ICON Plc
  • 14.5.3. Laboratory Corporation of America Holdings
  • 14.5.4. Charles River Laboratories International, Inc.
  • 14.5.5. PAREXEL International Corp.
  • 14.5.6. Syneos Health
  • 14.5.7. Medpace Holdings, Inc.
  • 14.5.8. Novotech
  • 14.5.9. Veristat, LLC.
  • 14.5.10. Veristat, LLC.

15. Strategic Recommendations